Journal ArticleDOI
Guidelines for the Management of Rheumatoid Arthritis 2002 Update
TLDR
The guideline reviewed in this month's column describes the recommended care of patients who have been previously diagnosed with RA.Abstract:
Rheumatoid arthritis (RA) is a progressive polyarthritis that is responsible for over nine million office visits annually. It is likely that most nurse practitioners will care for one or more patients with RA because approximately 1% of the adult population is affected by this disabling disorder. The guideline reviewed in this month's column describes the recommended care of patients who have been previously diagnosed with RA.read more
Citations
More filters
Journal ArticleDOI
Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study).
Tsutomu Takeuchi,Yoshiya Tanaka,Yuko Kaneko,Eiichi Tanaka,Shintaro Hirata,Takahiko Kurasawa,Satoshi Kubo,Kazuyoshi Saito,Kumi Shidara,Noriko Kimura,Hayato Nagasawa,Hideto Kameda,Koichi Amano,Hisashi Yamanaka +13 more
TL;DR: ADA therapy is highly effective for reducing disease activity, improving physical function, and limiting radiographic progression, and is generally safe and well tolerated by Japanese RA patients in routine clinical practice.
Journal ArticleDOI
The Management of Chronic Pain in Important Patient Subgroups
TL;DR: The use of mild opioids, such as codeine and tramadol, and strong opioids,such as morphine, hydromorphone and oxycodone, may be appropriate where paracetamol and other non-opioid analgesics are ineffective in chronic non-cancer pain.
Journal ArticleDOI
Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis.
Tsuyoshi Odai,Mizuho Matsunawa,Ryo Takahashi,Kuninobu Wakabayashi,Takeo Isozaki,Nobuyuki Yajima,Yusuke Miwa,Tsuyoshi Kasama +7 more
TL;DR: The results suggest that the CX3CL1-CX3CR1 system in patients with active RA may be sensitive to anti-tumor necrosis factor-α therapy, and confirm that CX 3CL1 plays a crucial role in the pathogenesis of RA.
Journal ArticleDOI
Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatic drugs--results of the British Rheumatoid Outcome Study Group randomized controlled clinical trial.
Deborah P M Symmons,K. Tricker,Mark Harrison,Chris Roberts,M J Davis,P. T. Dawes,Andrew Hassell,Samantha J. L. Knight,Diarmuid Mulherin,David Scott +9 more
TL;DR: The trial showed no additional benefit of intensified treatment with traditional disease modifying anti-rheumatic drugs (DMARDs) in patients with stable, established RA and it proved hard to suppress C-reactive protein levels.
Journal ArticleDOI
Influence of Methotrexate Dose on Its Efficacy and Safety in Rheumatoid Arthritis Patients: Evidence Based on the Variety of Prescribing Approaches Among Practicing Japanese Rheumatologists in a Single Institute-Based Large Observational Cohort (IORRA)
Hisashi Yamanaka,Eisuke Inoue,Eiichi Tanaka,Ayako Nakajima,Atsuo Taniguchi,Chihiro Terai,Masako Hara,Taisuke Tomatsu,Naoyuki Kamatani +8 more
TL;DR: This study demonstrated that extensive methotrexate use effectively suppressed RA disease activity and inhibits disability progression and found that it is critical to pay attention to patient-reported adverse reactions.
References
More filters
Journal ArticleDOI
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
Frank C. Arnett,Steven M. Edworthy,Daniel A. Bloch,Dennis J. McShane,James F. Fries,Norman S. Cooper,L. A. Healey,Stephen R. Kaplan,Matthew H. Liang,Harvinder S. Luthra,Thomas A. Medsger,Donald M. Mitchell,David H. Neustadt,Robert S. Pinals,Jane G. Schaller,John T. Sharp,Ronald L. Wilder,Gene G. Hunder +17 more
TL;DR: The revised criteria for the classification of rheumatoid arthritis (RA) were formulated from a computerized analysis of 262 contemporary, consecutively studied patients with RA and 262 control subjects with rheumatic diseases other than RA (non-RA).
Journal ArticleDOI
Measurement of patient outcome in arthritis.
TL;DR: A structure for representation of patient outcome is presented, together with a method for outcome measurement and validation of the technique in rheumatoid arthritis, and these techniques appear extremely useful for evaluation of long term outcome of patients with rheumatic diseases.
Journal ArticleDOI
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
Claire Bombardier,Loren Laine,Alise S. Reicin,Deborah R. Shapiro,Ruben Burgos-Vargas,Barry R. Davis,Richard O. Day,Marcos Bosi Ferraz,Christopher J. Hawkey,Marc C. Hochberg,Tore K Kvien,Thomas J. Schnitzer +11 more
TL;DR: In patients with rheumatoid arthritis, treatment with rofecoxib, a selective inhibitor of cyclooxygenase-2, is associated with significantly fewer clinically important upper gastrointestinal events than treatment with naproxen, a nonselective inhibitor.
Journal ArticleDOI
Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial
Fred E. Silverstein,Gerald A. Faich,Jay L. Goldstein,Lee S. Simon,Theodore Pincus,Andrew Whelton,Robert W. Makuch,Glenn M. Eisen,Naurang M. Agrawal,William F. Stenson,Aimee M. Burr,William W. Zhao,Jeffrey D. Kent,James B. Lefkowith,Kenneth M. Verburg,G. Steven Geis +15 more
TL;DR: In this study, celecoxib, at dosages greater than those indicated clinically, was associated with a lower incidence of symptomatic ulcers and ulcer complications combined, as well as other clinically important toxic effects, compared with NSAIDs at standard dosages.
Journal ArticleDOI
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
Ravinder N. Maini,E W St Clair,F. C. Breedveld,Daniel E. Furst,Joachim R. Kalden,Michael H. Weisman,Josef S. Smolen,Paul Emery,G Harriman,Marc Feldmann,Peter E. Lipsky +10 more
TL;DR: Infliximab was well-tolerated; withdrawals for adverse events as well as the occurrence of serious adverse events or serious infections did not exceed those in the placebo group.
Related Papers (5)
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
Frank C. Arnett,Steven M. Edworthy,Daniel A. Bloch,Dennis J. McShane,James F. Fries,Norman S. Cooper,L. A. Healey,Stephen R. Kaplan,Matthew H. Liang,Harvinder S. Luthra,Thomas A. Medsger,Donald M. Mitchell,David H. Neustadt,Robert S. Pinals,Jane G. Schaller,John T. Sharp,Ronald L. Wilder,Gene G. Hunder +17 more